Skip to content
DataLookout
Menu

FIRSTNCT06399809

Fisetin to Reduce Senescence and Mobility Impairment in PAD

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 7 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Nov 2026 to Jun 30, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 30 words
    • Study completion pushed from Jun 2027 to Aug 31, 2027
    • Secondary endpoints: details revised at 3 of 4 entries
    • Site contact updated
  2. Minor Site contact updatedv4
  3. Notable Start date: Jul 16, 2024 to Sep 30, 2024v3 Show 5 more changesShow less
    • Eligibility criteria expanded, about 30 words
    • Primary completion date: Nov 30, 2026 to Nov 2026
    • Study completion date: Jun 30, 2027 to Jun 2027
    • Site contact updated
    • Study description shortened, about 1 word
  4. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Eligibility criteria expanded, about 11 words
    • Start date changed from estimate of Jun 1, 2024 to Jul 16, 2024
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study description revised
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Six-minute Walk Distance
Timeframe: Measured at baseline and 4 month follow-up

Secondary (4)

Hand Grip Strength
Short physical performance battery (SPPB)
Number of cells with senescence markers
Gastrocnemius perfusion

Arms and interventions

FisetinExperimental

Sharp Clinical Services will provide fisetin (100 mg capsules). Randomized participants will receive fisetin 20 mgs/kg once daily for two days, followed by 12 days without therapy. Fisetin will be dosed in 100 mg tablets. Dosing will be rounded to the nearest 100 mg. For example, a 73 kg participant with a dose of 1,460 mg (i.e.73 kg x 20 mg) receives 1,500 mgs daily (i.e. 15 x 100 mg capsules) for two days every 14 days.

PlaceboPlacebo comparator

Sharp Clinical Services will provide placebo (100 mg capsules). Randomized participants will receive placebo 20 mgs/kg once daily for two days, followed by 12 days without therapy. Placebo will be dosed in 100 mg tablets. Dosing will be rounded to the nearest 100 mg. For example, a 73 kg participant with a dose of 1,460 mg (i.e.73 kg x 20 mg) receives 1,500 mgs daily (i.e. 15 x 100 mg capsules) for two days every 14 days.

Drugs: Fisetin, Placebo

Sites

1 site in 1 country

  • Northwestern University Feinberg School of MedicineChicago, Illinois, United States